MedPath

Effectiveness of Gradual Versus Rapid Weight Loss

Not Applicable
Active, not recruiting
Conditions
Obesity
Interventions
Other: Gradual weight loss (GWL) program
Other: Rapid weight loss (RWL) program
Registration Number
NCT03776552
Lead Sponsor
The Hospital of Vestfold
Brief Summary

This randomized controlled trial aims to compare the 1-year effectiveness of an initial rapid weight loss (RWL) program and a gradual weight loss (GWL) program.

Detailed Description

A total of at least 286 participants will be randomized to either a 16-week rapid weight loss (RWL) program; \[an 8-week low-energy-diet (\<1000 kcal/day) - followed by an 8-week gradual increase in energy intake (4 weeks \<1300 kcal/day and 4 weeks \<1500 kcal/day)\], or a 16-week gradual weight loss (GWL) program (controls); \[estimated total energy expenditure minus 800-1000 kcal/day\]. Thereafter, all participants (both groups) will undergo a 36-week comprehensive weight maintenance program.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
293
Inclusion Criteria
  • • Willing and able to give informed consent for participation in the study

    • Living in the eastern part of Norway, mainly Oslo, Buskerud, Vestfold and Akershus
    • Understanding Norwegian language written and spoken easily
    • BMI ≥30.0 kg/m2
    • Stable body weight (<5 kg self-reported weight change) during the last 3 months before inclusion
Exclusion Criteria
  • • Pregnancy and breast-feeding mothers

    • Suspected non-compliance with regards to visits and/or diet
    • Severe chronic disease (endocrine disease, heart disease, neurological disease, lung disease, disease in the gastrointestinal tract, kidney disease, rheumatism or cancer).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Gradual weight loss (GWL) programGradual weight loss (GWL) program16-week GWL-program (estimated total energy expenditure minus 800-1000 kcal/day) followed by a 36-weight loss maintenance program.
Rapid weight loss (RWL) programRapid weight loss (RWL) program16-week rapid weight loss (RWL) program \[8-week LED (\<1000 kcal/day) - followed by an 8-week gradual increase in energy intake (4 weeks \<1300 kcal/day and 4 weeks \<1500 kcal/day)\] followed by a 36-weight loss maintenance program.
Primary Outcome Measures
NameTimeMethod
Change in body weight from baseline to 12 monthsBaseline to 1-year

Percent total body weight loss (%TBWL) at 12 months follow-up

Secondary Outcome Measures
NameTimeMethod
Changes in blood pressure4-month and 1-year

Systolic and diastolic blood pressure (mm/Hg)

Changes in glucose parameters4-month and 1-year

HbA1c (mmol/mol)

Changes in lipids4-month and 1-year

Total-cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides (mmol/l)

Changes in body composition 24-month and 1-year

Dual-energy X-ray Absorptiometry (DXA) in selected participants

Changes in CRP4-month and 1-year

CRP (mg/L)

Changes in Health Related Quality of Life 14-month and 1-year

Generic questionnaire: Short Form-36 Health Survey, SF36. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores for each of the 8 domains and summary scores for physical and mental health will be calculated

Changes in Health Related Quality of Life 34-month and 1-year

Weight-related Symptom Measure (WRSM). The validated obesity specific WRSM measures 20 symptoms commonly related to being overweight or obese, including foot problems, joint pain, sensitivity to cold, shortness of breath, etc. using two different sets of items. The first set assesses whether or not a patient is experiencing specific symptoms, and the second set rates the level of the distress of the symptoms with values from zero ("not at all") to six ("bothers a very great deal"). The first set creates an additive scale summing symptoms from 0-20, while the second forms a symptom distress scale ranging from 0-120.

Proportions of participants with a TBWL of ≥ 5%, ≥10% and ≥15% at 52-week1-year

TBWL of ≥ 5%, ≥10% and ≥15% at 52-week follow-up

Changes in anthropometric measures4-month and 1-year

Waist and hip circumference (cm)

Changes in body composition 14-month and 1-year

Bioelectrical Impedance Analysis (BIA)

Change in weight from baseline to 4 months4-month

Percent total body weight loss (%TBWL) at 4 months follow-up

Changes in Health Related Quality of Life 24-month and 1-year

Obesity specific questionnaire: IWQOL-lite. The IWQOL-Lite is a 31-item measure of weight-related quality of life. There are five domain scores (Physical Function, Self-Esteem, Sexual Life, Public Distress and Work) and a total score. Scores for all domains and total score range from 0-100, with lower scores indicating greater impairment.

Changes in symptoms of depression and anxiety4-month and 1-year

Hospital Anxiety and Depression Scale (HADS). The validated generic HADS measures symptoms of anxiety and depression using 14 items scored from 0-3 It is decomposed into two domains measuring depression (HADS-D) and anxiety (HADS-A), both consisting of seven items yielding a score from 0-21.

Changes in eating behavior4-month and 1-year

The Three Factor Eating Questionnaire -R 21 (TFEQ-R21) measures eating behaviour and has been validated for use in individuals with obesity and will be used in the study. It consists of 21 items comprising three domain scores; (1) uncontrolled eating; assessing the tendency to lose control over eating when feeling hungry or when exposed to external stimuli, (2) cognitive restraint; assessing the conscious restriction of food intake to control body weight or body shape, and (3) emotional eating; assessing overeating related to negative mood states. The domain scores were transformed to 0-100 scales to facilitate comparison; a higher score indicates more uncontrolled, restraint, or emotional eating.

Trial Locations

Locations (1)

Vestfold Hospital Trust

🇳🇴

Tønsberg, Norway

© Copyright 2025. All Rights Reserved by MedPath